Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
J Neurogastroenterol Motil ; 29(1): 72-84, 2023 Jan 30.
Article in English | MEDLINE | ID: mdl-36606438

ABSTRACT

Background/Aims: Chronic psychological stress affects gastrointestinal physiology which may underpin alterations in the immune response and epithelial transport, both functions are partly regulated by enteric nervous system. However, its effects on enteric neuroplasticity are still unclear. This study aims to investigate the effects of chronic unpredictable psychological stress on intestinal motility and prominent markers of enteric function. Methods: Adult male C57BL/6J mice were exposed to 19 day of unpredictable stress protocol schedule of social defeat and overcrowding. We investigated the effects on plasma corticosterone, food intake, and body weight. In vivo gastrointestinal motility was assessed by fecal pellet output and by whole-gastrointestinal transit (using the carmine red method). Tissue monoamine level, neural and glial markers, neurotrophic factors, monoamine signaling, and Toll-like receptor expression in the proximal and distal colon, and terminal ileum were also assessed. Results: Following chronic unpredictable psychological stress, stressed mice showed increased food intake and body weight gain (P < 0.001), and reduced corticosterone levels (P < 0.05) compared to control mice. Stressed mice had reduced stool output without differences in water content, and showed a delayed gastrointestinal transit compared to control mice (P < 0.05). Stressed mice exhibited decreased mRNA expression of tyrosine hydroxylase (Th), brain-derived neurotrophic factor (Bdnf) and glial cell-derived neurotrophic factor (Gdnf), as well as Toll-like receptor 2 (Tlr2) compared to control (P < 0.05), only proximal colon. These molecular changes in proximal colon were associated with higher levels of monoamines in tissue. Conclusion: Unpredictable psychological chronic stress induces region-specific impairment in monoamine levels and neuroplasticity markers that may relate to delayed intestinal transit.

2.
Sci Rep ; 9(1): 16928, 2019 11 15.
Article in English | MEDLINE | ID: mdl-31729416

ABSTRACT

Increasing evidence suggests a role for inflammation in neuropsychiatric conditions including autism spectrum disorder (ASD), a neurodevelopmental syndrome with higher prevalence in males than females. Here we examined the effects of early-life immune system activation (EIA)-comprising regimens of prenatal, early postnatal, or combined ("two-hit") immune activation-on the core behavioral features of ASD (decreased social interaction, increased repetitive behavior, and aberrant communication) in C57BL/6J mice. We treated timed-pregnant mice with polyinosinic:polycytidylic acid (Poly I:C) on gestational day 12.5 to produce maternal immune activation (MIA). Some offspring also received lipopolysaccharide (LPS) on postnatal day 9 to produce postnatal immune activation (PIA). EIA produced disruptions in social behavior and increases in repetitive behaviors that were larger in males than in females. Ultrasonic vocalizations (USVs) were altered in both sexes. Molecular studies revealed that EIA also produced prominent sex-specific changes in inflammation-related gene expression in the brain. Whereas both sexes showed increases in pro-inflammatory factors, as reflected by levels of mRNA and protein, expression of anti-inflammatory factors was decreased in males but increased in females. Our findings demonstrate that EIA can produce sex-specific behavioral effects and immune responses in the brain, and identify molecular processes that may contribute to resilience in females.


Subject(s)
Autistic Disorder/etiology , Autistic Disorder/psychology , Immunity , Maternal Exposure/adverse effects , Neuroimmunomodulation , Prenatal Exposure Delayed Effects , Animals , Behavior, Animal , Biomarkers , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Disease Susceptibility , Female , Gene Expression , Inflammation Mediators/metabolism , Male , Mice , Pregnancy , Sex Factors , Social Behavior
3.
J Neurosci ; 38(13): 3358-3372, 2018 03 28.
Article in English | MEDLINE | ID: mdl-29491010

ABSTRACT

Inflammatory processes may be involved in the pathophysiology of neuropsychiatric illnesses including autism spectrum disorder (ASD). Evidence from studies in rodents indicates that immune activation during early development can produce core features of ASD (social interaction deficits, dysregulation of communication, increases in stereotyped behaviors, and anxiety), although the neural mechanisms of these effects are not thoroughly understood. We treated timed-pregnant mice with polyinosinic:polycytidylic acid (Poly I:C), which simulates a viral infection, or vehicle on gestational day 12.5 to produce maternal immune activation (MIA). Male offspring received either vehicle or lipopolysaccharide, which simulates a bacterial infection, on postnatal day 9 to produce postnatal immune activation (PIA). We then used optogenetics to address the possibility that early developmental immune activation causes persistent alterations in the flow of signals within the mPFC to basolateral amygdala (BLA) pathway, a circuit implicated in ASD. We found that our MIA regimen produced increases in synaptic strength in glutamatergic projections from the mPFC to the BLA. In contrast, our PIA regimen produced decreases in feedforward GABAergic inhibitory postsynaptic responses resulting from activation of local circuit interneurons in the BLA by mPFC-originating fibers. Both effects were seen together when the regimens were combined. Changes in the balance between excitation and inhibition were differentially translated into the modified spike output of BLA neurons. Our findings raise the possibility that prenatal and postnatal immune activation may affect different cellular targets within brain circuits that regulate some of the core behavioral signs of conditions such as ASD.SIGNIFICANCE STATEMENT Immune system activation during prenatal and early postnatal development may contribute to the development of autism spectrum disorder (ASD). Combining optogenetic approaches and behavioral assays that reflect core features of ASD (anxiety, decreased social interactions), we uncovered mechanisms by which the ASD-associated behavioral impairments induced by immune activation could be mediated at the level of interactions within brain circuits implicated in control of emotion and motivation (mPFC and BLA, specifically). Here, we present evidence that prenatal and postnatal immune activation can have different cellular targets in the brain, providing support to the notion that the etiology of ASD may be linked to the excitation/inhibition imbalance in the brain affecting the signal flow within relevant behavior-driving neural microcircuits.


Subject(s)
Amygdala/physiopathology , Autism Spectrum Disorder/immunology , Prefrontal Cortex/physiopathology , Prenatal Exposure Delayed Effects/immunology , Synaptic Transmission , Amygdala/immunology , Animals , Autism Spectrum Disorder/etiology , Autism Spectrum Disorder/physiopathology , Female , GABAergic Neurons/metabolism , GABAergic Neurons/physiology , Interneurons/metabolism , Interneurons/physiology , Lipopolysaccharides/toxicity , Male , Mice , Mice, Inbred C57BL , Prefrontal Cortex/immunology , Pregnancy , Prenatal Exposure Delayed Effects/etiology , Prenatal Exposure Delayed Effects/physiopathology
4.
PLoS One ; 11(5): e0155367, 2016.
Article in English | MEDLINE | ID: mdl-27159520

ABSTRACT

Exposure to high-fat diet induces both, peripheral and central alterations in TLR4 expression. Moreover, functional TLR4 is required for the development of high-fat diet-induced obesity. Recently, central alterations in TLR4 expression have been associated with the modulation of visceral pain. However, it remains unknown whether there is a functional interaction between the role of TLR4 in diet-induced obesity and in visceral pain. In the present study we investigated the impact of long-term exposure to high-fat diet on visceral pain perception and on the levels of TLR4 and Cd11b (a microglial cell marker) protein expression in the prefrontal cortex (PFC) and hippocampus. Peripheral alterations in TLR4 were assessed following the stimulation of spleenocytes with the TLR4-agonist LPS. Finally, we evaluated the effect of blocking TLR4 on visceral nociception, by administering TAK-242, a selective TLR4-antagonist. Our results demonstrated that exposure to high-fat diet induced visceral hypersensitivity. In parallel, enhanced TLR4 expression and microglia activation were found in brain areas related to visceral pain, the PFC and the hippocampus. Likewise, peripheral TLR4 activity was increased following long-term exposure to high-fat diet, resulting in an increased level of pro-inflammatory cytokines. Finally, TLR4 blockage counteracted the hyperalgesic phenotype present in mice fed on high-fat diet. Our data reveal a role for TLR4 in visceral pain modulation in a model of diet-induced obesity, and point to TLR4 as a potential therapeutic target for the development of drugs to treat visceral hypersensitivity present in pathologies associated to fat diet consumption.


Subject(s)
Diet, High-Fat , Obesity/physiopathology , Toll-Like Receptor 4/physiology , Visceral Pain/physiopathology , Animals , Brain/physiopathology , Male , Mice , Mice, Inbred C57BL
5.
Handb Exp Pharmacol ; 228: 309-34, 2015.
Article in English | MEDLINE | ID: mdl-25977088

ABSTRACT

The purpose of this chapter is to present results from recent research on social cognition in autism spectrum disorder (ASD). The clinical phenomenology and neuroanatomical circuitry of ASD are first briefly described. The neuropharmacology of social cognition in animal models of ASD and humans is then addressed. Next, preclinical and clinical research on the neurohormone oxytocin is reviewed. This is followed by a presentation of results from preclinical and clinical studies on the excitatory amino acid glutamate. Finally, the role of neuroinflammation in ASD is addressed from the perspectives of preclinical neuroscience and research involving humans with ASD.


Subject(s)
Brain/drug effects , Child Development Disorders, Pervasive/drug therapy , Cognition/drug effects , Interpersonal Relations , Nootropic Agents/therapeutic use , Social Behavior , Animals , Behavior, Animal/drug effects , Brain/metabolism , Brain/physiopathology , Child Development Disorders, Pervasive/metabolism , Child Development Disorders, Pervasive/physiopathology , Child Development Disorders, Pervasive/psychology , Disease Models, Animal , Humans , Neural Pathways/drug effects , Neural Pathways/physiopathology
6.
J Neurosci ; 35(11): 4599-613, 2015 Mar 18.
Article in English | MEDLINE | ID: mdl-25788677

ABSTRACT

Neuropeptide S (NPS) has generated substantial interest due to its anxiolytic and fear-attenuating effects in rodents, while a corresponding receptor polymorphism associated with increased NPS receptor (NPSR1) surface expression and efficacy has been implicated in an increased risk of panic disorder in humans. To gain insight into this paradox, we examined the NPS system in rats and mice bred for high anxiety-related behavior (HAB) versus low anxiety-related behavior, and, thereafter, determined the effect of central NPS administration on anxiety- and fear-related behavior. The HAB phenotype was accompanied by lower basal NPS receptor (Npsr1) expression, which we could confirm via in vitro dual luciferase promoter assays. Assessment of shorter Npsr1 promoter constructs containing a sequence mutation that introduces a glucocorticoid receptor transcription factor binding site, confirmed via oligonucleotide pull-down assays, revealed increased HAB promoter activity-an effect that was prevented by dexamethasone. Analogous to the human NPSR1 risk isoform, functional analysis of a synonymous single nucleotide polymorphism in the coding region of HAB rodents revealed that it caused a higher cAMP response to NPS stimulation. Assessment of the behavioral consequence of these differences revealed that intracerebroventricular NPS reversed the hyperanxiety of HAB rodents as well as the impaired cued-fear extinction in HAB rats and the enhanced fear expression in HAB mice, respectively. These results suggest that alterations in the NPS system, conserved across rodents and humans, contribute to innate anxiety and fear, and that HAB rodents are particularly suited to resolve the apparent discrepancy between the preclinical and clinical findings to date.


Subject(s)
Anxiety/genetics , Anxiety/metabolism , Breeding , Polymorphism, Single Nucleotide/genetics , Receptors, G-Protein-Coupled/genetics , Acoustic Stimulation/methods , Animals , Anxiety/psychology , Breeding/methods , Fear/physiology , Fear/psychology , HEK293 Cells , Humans , Male , Mice , Rats
7.
Brain Res ; 1617: 72-92, 2015 Aug 18.
Article in English | MEDLINE | ID: mdl-25445995

ABSTRACT

A role for immunological involvement in autism spectrum disorder (ASD) has long been hypothesized. This review includes four sections describing (1) evidence for a relationship between familial autoimmune disorders and ASD; (2) results from post-mortem and neuroimaging studies that investigated aspects of neuroinflammation in ASD; (3) findings from animal model work in ASD involving inflammatory processes; and (4) outcomes from trials of anti-inflammatory/immune-modulating drugs in ASD that have appeared in the literature. Following each section, ideas are provided for future research, suggesting paths forward in the continuing effort to define the role of immune factors and inflammation in the pathophysiology of a subtype of ASD. This article is part of a Special Issue entitled SI: Neuroimmunology in Health And Disease.


Subject(s)
Autism Spectrum Disorder/immunology , Autoimmune Diseases/complications , Animals , Anti-Inflammatory Agents/therapeutic use , Autism Spectrum Disorder/drug therapy , Autism Spectrum Disorder/etiology , Autism Spectrum Disorder/genetics , Autoimmune Diseases/genetics , Brain/immunology , Brain/pathology , Disease Models, Animal , Encephalitis/complications , Encephalitis/immunology , Encephalitis/pathology , Humans , Inflammation/immunology , Interferon Inducers/therapeutic use
8.
Biol Psychiatry ; 76(4): 340-8, 2014 Aug 15.
Article in English | MEDLINE | ID: mdl-24331544

ABSTRACT

BACKGROUND: Functional gastrointestinal disorders, which have visceral hypersensitivity as a core symptom, are frequently comorbid with stress-related psychiatric disorders. Increasing evidence points to a key role for toll-like receptor 4 (TLR4) in chronic pain states of somatic origin. However, the central contribution of TLR4 in visceral pain sensation remains elusive. METHODS: With pharmacological and genetic approaches, we investigated the involvement of TLR4 in the modulation of visceral pain. The TLR4-deficient and wild-type mice were exposed to chronic stress. Visceral pain was evaluated with colorectal distension. Protein expression levels for TLR4, Cd11b, and glial fibrillary acidic protein (glial cells markers) were quantified in the lumbar region of the spinal cord, prefrontal cortex (PFC), and hippocampus. To evaluate the effect of blocking TLR4 on visceral nociception, TAK-242, a selective TLR4 antagonist, was administered peripherally (intravenous) and centrally (intracerebroventricular and intra-PFC) (n = 10-12/experimental group). RESULTS: The TLR4 deficiency reduced visceral pain and prevented the development of chronic psychosocial stress-induced visceral hypersensitivity. Increased expression of TLR4 coupled with enhanced glia activation in the PFC and increased levels of proinflammatory cytokines were observed after chronic stress in wild-type mice. Administration of a TLR4 specific antagonist, TAK-242, attenuated visceral pain sensation in animals with functional TLR4 when administrated centrally and peripherally. Moreover, intra-PFC TAK-242 administration also counteracted chronic stress-induced visceral hypersensitivity. CONCLUSIONS: Our results reveal a novel role for TLR4 within the PFC in the modulation of visceral nociception and point to TLR4 as a potential therapeutic target for the development of drugs to treat visceral hypersensitivity.


Subject(s)
Prefrontal Cortex/physiopathology , Stress, Psychological/complications , Toll-Like Receptor 4/metabolism , Visceral Pain/etiology , Visceral Pain/physiopathology , Analgesics/pharmacology , Animals , CD11b Antigen/metabolism , Chronic Disease , Dominance-Subordination , Glial Fibrillary Acidic Protein , Hippocampus/drug effects , Hippocampus/physiopathology , Lumbar Vertebrae , Male , Mice, Inbred C3H , Mice, Knockout , Nerve Tissue Proteins/metabolism , Prefrontal Cortex/drug effects , Spinal Cord/drug effects , Spinal Cord/physiopathology , Stress, Psychological/physiopathology , Sulfonamides/pharmacology , Toll-Like Receptor 4/antagonists & inhibitors , Toll-Like Receptor 4/genetics , Visceral Pain/drug therapy
9.
Pharmacol Ther ; 135(3): 316-26, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22749794

ABSTRACT

The neuronal circuitry underlying the complex relationship between stress, mood and food intake are slowly being unravelled and several studies suggest a key role herein for the peripherally derived hormone, ghrelin. Evidence is accumulating linking obesity as an environmental risk factor to psychiatric disorders such as stress, anxiety and depression. Ghrelin is the only known orexigenic hormone from the periphery to stimulate food intake. Plasma ghrelin levels are enhanced under conditions of physiological stress and ghrelin has recently been suggested to play an important role in stress-induced food reward behaviour. In addition, chronic stress or atypical depression has often demonstrated to correlate with an increase in ingestion of caloric dense 'comfort foods' and have been implicated as one of the major contributor to the increased prevalence of obesity. Recent evidence suggests ghrelin as a critical factor at the interface of homeostatic control of appetite and reward circuitries, modulating the hedonic aspects of food intake. Therefore, the reward-related feeding of ghrelin may reveal itself as an important factor in the development of addiction to certain foods, similar to its involvement in the dependence to drugs of abuse, including alcohol. This review will highlight the accumulating evidence demonstrating the close interaction between food, mood and stress and the development of obesity. We consider the ghrelinergic system as an effective target for the development of successful anti-obesity pharmacotherapies, which not only affects appetite but also selectively modulates the rewarding properties of food and impact on psychological well-being in conditions of stress, anxiety and depression.


Subject(s)
Affect/physiology , Ghrelin/physiology , Obesity/physiopathology , Reward , Stress, Psychological/physiopathology , Animals , Behavior, Addictive/physiopathology , Eating/physiology , Homeostasis/physiology , Humans , Models, Biological , Signal Transduction/physiology
10.
Psychopharmacology (Berl) ; 220(1): 173-81, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21892647

ABSTRACT

RATIONAL: The ghrelinergic system is implicated in the development of obesity and in modulating central reward systems. It has been reported that diet-induced obesity causes blunted responding on food intake to ghrelin administration, associated with central ghrelin resistance. Here we investigate whether the stimulatory effects of ghrelin on the reward system are altered in diet-induced obese mice. METHODS: Obesity was induced in C57BL/6J mice by feeding high-fat diet for 13 weeks. Mice were trained in an operant fixed and exponential progressive ratio task to respond for sucrose rewards. In an ad libitum fed state, ghrelin and a ghrelin receptor antagonist were administered in the progressive ratio. Alterations in the central ghrelin system in diet-induced obese mice were assessed. RESULTS: Obese mice showed attenuated acquisition and performance in the fixed and progressive ratio paradigm. Most importantly, diet-induced obesity inhibited the stimulatory effects of ghrelin (2 nmol, 3 nmol/10 g) on progressive ratio responding whereas lean animals presented with increased responding. Administration of the ghrelin-receptor antagonist (D-Lys(3))-GHRP-6 (66.6 nmol/10 g) decreased performance in lean but not obese mice. This insensitivity to ghrelin receptor ligands in mice on high-fat diet was further supported by decreased mRNA expression of the ghrelin receptor in the hypothalamus and the nucleus accumbens in obese mice. CONCLUSIONS: This study demonstrates that the modulatory effects of ghrelin receptor ligands are blunted in a mouse model of diet-induced obesity in a progressive ratio task. Thereby, our data extend the previously described ghrelin resistance in these mice from food intake to reward-associated behaviours.


Subject(s)
Ghrelin/pharmacology , Obesity/metabolism , Receptors, Ghrelin/metabolism , Reward , Animals , Behavior, Animal/drug effects , Diet, High-Fat/adverse effects , Dose-Response Relationship, Drug , Gene Expression Regulation , Ghrelin/administration & dosage , Ghrelin/metabolism , Hypothalamus/metabolism , Male , Mice , Mice, Inbred C57BL , Nucleus Accumbens/metabolism , Obesity/etiology , Oligopeptides/pharmacology , RNA, Messenger/metabolism , Receptors, Ghrelin/drug effects , Receptors, Ghrelin/genetics , Sucrose/administration & dosage
11.
Int J Neuropsychopharmacol ; 15(3): 375-87, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21708052

ABSTRACT

Neuropeptide S (NPS) and its receptor (NPSR) have been implicated in the mediation of anxiolytic-like behaviour in rodents. However, little knowledge is available regarding the NPS system in depression-related behaviours, and whether NPS also exerts anxiolytic effects in an animal model of psychopathology. Therefore, the aim of this work was to characterize the effects of NPS on depression- and anxiety-related parameters, using male and female rats in a well-validated animal model of depression: the Flinders Sensitive Line (FSL), their controls, the Flinders Resistant Line (FRL), and Sprague-Dawley (SD) rats. We found that FSL showed greater immobility in the forced swim test (FST) than FRL, confirming their phenotype. However, NPS did not affect depression-related behaviour in any rat line. No significant differences in baseline anxiety levels between the FSL and FRL strains were observed, but FSL and FRL rats displayed less anxiety-like behaviour compared to SD rats. NPS decreased anxiety-like behaviour on the elevated plus-maze in all strains. The expression of the NPSR in the amygdala, periventricular hypothalamic nucleus, and hippocampus was equal in all male strains, although a trend towards reduced expression within the amygdala was observed in FSL rats compared to SD rats. In conclusion, NPS had a marked anxiolytic effect in FSL, FRL and SD rats, but did not modify the depression-related behaviour in any strain, in spite of the significant differences in innate level between the strains. These findings suggest that NPS specifically modifies anxiety behaviour but cannot overcome/reverse a genetically mediated depression phenotype.


Subject(s)
Anti-Anxiety Agents/administration & dosage , Anxiety Disorders/drug therapy , Anxiety Disorders/physiopathology , Depressive Disorder/drug therapy , Depressive Disorder/physiopathology , Neuropeptides/administration & dosage , Animals , Brain/drug effects , Brain/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Female , Genetic Predisposition to Disease , Male , Maze Learning/drug effects , Maze Learning/physiology , Motor Activity/drug effects , Motor Activity/physiology , Neuropsychological Tests , Rats, Inbred Strains , Rats, Sprague-Dawley , Receptors, Neuropeptide/metabolism , Sex Characteristics , Species Specificity , Swimming/physiology
12.
Psychoneuroendocrinology ; 37(6): 729-41, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21783325

ABSTRACT

BACKGROUND: Chronic stress and diet can independently or in concert influence the body's homeostasis over time. Thus, it is crucial to investigate the interplay of these parameters to gain insight into the evolution of stress-induced metabolic and eating disorders. METHODS: C57BL/6J mice were subjected to chronic psychosocial (mixed model of social defeat and overcrowding) stress in combination with either a high- or low-fat diet for three or six weeks. To determine the evolution of stress and dietary effects, changes in body weight, caloric intake and caloric efficiency were determined as well as circulating leptin, insulin, glucose and corticosterone levels and social avoidance behaviour. RESULTS: Exposure to stress for three weeks caused an increase in weight gain, in caloric intake and in caloric efficiency only in mice on a low-fat diet. However, after six weeks, only stressed mice on a high-fat diet displayed a pronounced inhibition of body weight gain, accompanied by reduced caloric intake and caloric efficiency. Stress decreased circulating leptin levels in mice on a low-fat diet after three weeks and in mice on a high-fat diet after three and six weeks of exposure. Plasma levels of insulin and markers of insulin resistance were blunted in mice on high-fat diet following six weeks of stress exposure. Social avoidance following chronic stress was present in all mice after three and six weeks. CONCLUSIONS: This study describes the evolution of the chronic effects of social defeat/overcrowding stress in combination with exposure to high- or low-fat diet. Most importantly, we demonstrate that a six week chronic exposure to social defeat stress prevents the metabolic effects of high-fat diet, by inhibiting an increase in weight gain, caloric intake and efficiency and insulin resistance as well as in plasma leptin and insulin levels. This study highlights the importance of considering the chronic aspects of both parameters and their time-dependent interplay.


Subject(s)
Body Weight/physiology , Diet, High-Fat , Stress, Psychological/physiopathology , Animals , Blood Glucose/metabolism , Chronic Disease , Corticosterone/blood , Crowding/psychology , Energy Intake , Insulin/blood , Interpersonal Relations , Leptin/blood , Male , Mice , Mice, Inbred C57BL , Social Dominance , Social Environment , Weight Gain/physiology
13.
Behav Pharmacol ; 22(7): 624-32, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21897203

ABSTRACT

Behavioral satiety sequence (BSS) is a useful paradigm to assess the effects of orexigenic and anorexigenic profiles of novel pharmacological and genetic manipulations in rodents. To date, no studies have described the satiety profile of leptin-deficient ob/ob mice, an important animal model of obesity in this task. Furthermore, no studies have described changes in the BSS after treatment with ghrelin receptor ligands, which have become an attractive therapeutic target in obesity drug discovery efforts. BSS testing was carried out in ob/ob mice and their lean controls. After baseline analysis, effects of ghrelin (2 nmol/10 g) and of the ghrelin receptor antagonist (D-Lys)-GHRP-6 (66.6 and 133.3 nmol/10 g) were studied in BSS in mice of both genotypes. The baseline BSS profile of ob/ob mice showed an increased eating and a decreased resting activity. Ob/ob mice presented with a decreased sensitivity to the stimulation with ghrelin and with the ghrelin receptor antagonist, which caused strong anorexic and adverse side effects in lean mice, thereby disrupting the BSS profile. BSS is an indispensable tool for parsing the role of the ghrelinergic system in satiety, to characterize transgenic mice and to elicit behavioral feeding profiles of novel anorectic agents.


Subject(s)
Appetite Depressants/pharmacology , Behavior, Animal , Ghrelin/physiology , Obesity/physiopathology , Oligopeptides/pharmacology , Satiation , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Eating/physiology , Fasting/physiology , Leptin/genetics , Ligands , Male , Mice , Mice, Knockout , Mice, Obese , Obesity/drug therapy , Obesity/genetics , Receptors, Ghrelin/antagonists & inhibitors , Receptors, Ghrelin/genetics , Receptors, Ghrelin/metabolism , Time Factors
14.
Psychopharmacology (Berl) ; 216(3): 421-9, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21373788

ABSTRACT

BACKGROUND: Several fine-tuned and interconnected hypothalamic peptidergic systems orchestrate the regulation of energy homeostasis in the body. The orexigenic peptide ghrelin and the anorexigenic peptide leptin are among the most important, and both have been implicated in the development of eating disorders from obesity to anorexia nervosa. OBJECTIVES: The goal of these studies was to examine the response of leptin-deficient ob/ob mice in ghrelin-receptor ligands in a food intake task. METHODS: Changes in cumulative food intake were measured after peripheral administration of ghrelin (1 and 2 nmol/10 g) and the ghrelin-receptor antagonist (D-Lys(3))-GHRP-6 (66.6 and 133.3 nmol/10 g) in obese and lean control mice during the light and dark cycle as well as in a state of food restriction. Hypothalamic ghrelin and ghrelin-receptor expression was measured in ob/ob and lean mice at two different timepoints. RESULTS: Ghrelin increased food intake in lean and obese mice in the light and dark cycle, whereas the ghrelin-receptor antagonist caused significantly stronger reduction in food intake in obese mice only in the dark cycle. After fasting, ob/ob mice displayed decreased light cycle sensitivity to the anorexigenic effects of the ghrelin-receptor antagonist. Hypothalamic expression levels of ghrelin were unaltered during the light cycle but decreased during the dark cycle in ob/ob mice; whereas, although unchanged in the light cycle, ghrelin-receptor expression was increased in the dark cycle in obese mice. CONCLUSION: The functionality and sensitivity of the ghrelinergic system is dependent on the time of day and the satiety state in leptin-deficient ob/ob mice.


Subject(s)
Eating/drug effects , Leptin/deficiency , Obesity/metabolism , Photoperiod , Receptors, Ghrelin/antagonists & inhibitors , Satiation/drug effects , Animals , Disease Models, Animal , Ghrelin/genetics , Ghrelin/pharmacology , Hypothalamus/metabolism , Ligands , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Obesity/physiopathology , Oligopeptides/pharmacology , Real-Time Polymerase Chain Reaction , Receptors, Ghrelin/genetics
15.
Neuropharmacology ; 59(7-8): 619-26, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20727362

ABSTRACT

The progressive ratio schedule of operant responding is a well utilised task for assessing the rewarding aspects of abused drugs and natural rewards including food. Interestingly, progressive ratio paradigms have mainly been neglected in the field of animal research in obesity. Among the most widely studied mouse models of obesity is the leptin-deficient ob/ob mouse, characterised by hyperphagia and obesity. To date there are no studies on the behaviour of these mice in progressive ratio responding, thus we sought to validate the utility of the progressive ratio paradigm in obese mice and demonstrate its sensitivity to an anorectic drug challenge. Ob/ob mice and their lean controls were tested in fixed ratio paradigms of different demand, extinction learning, and progressive ratio schedules with linear and exponential increments, followed by an anorectic drug challenge with fenfluramine (5 and 10 mg/kg). Obese animals showed equal fixed ratio-acquisition and -responding for ratios 1 and 3, but displayed lower responding in ratios 6 and 9. Interestingly, obese animals showed equal motivation to respond in progressive ratio schedules. Fenfluramine dose-dependently induced anorectic effects in both genotypes and reduced progressive ratio responding significantly. This study, for the first time, describes motivational food intake in an operant progressive ratio paradigm in ob/ob mice. Leptin deficiency did not alter appetitive learning or motivation in the progressive ratio. The utility and sensitivity of the progressive ratio task for studies on motivational food intake was demonstrated by a challenge with the anorectic agent fenfluramine.


Subject(s)
Appetite Depressants/pharmacology , Conditioning, Operant/drug effects , Fenfluramine/pharmacology , Obesity/psychology , Animals , Appetitive Behavior/drug effects , Extinction, Psychological/drug effects , Learning/drug effects , Leptin/genetics , Male , Mice , Mice, Obese , Motivation/drug effects , Reward
16.
Psychopharmacology (Berl) ; 210(4): 559-68, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20422404

ABSTRACT

RATIONALE: The individual's emotional state influences food intake in both humans and rodents. Moreover, specific cognitive processes regulating the salient aspects of food reward are also critical for ingestive behaviour. However, the molecular mechanisms underlying such influence remain unclear. Genetic mouse models thus are important tools in dissecting the molecular and pathophysiological processes which cause complex human diseases. Leptin, encoded by the ob gene, plays an important part in the energy homeostasis and is critical for the development of obesity. OBJECTIVES: In these studies, we assess the impact of leptin on behaviours relevant to anxiety and appetitive learning. METHODS: Anxiety-related behaviour was assessed in the light dark box and two tests of hyponeophagia. Spatial learning and behavioural flexibility by re-learning was assessed in an appetitive Y-maze task. RESULTS: Leptin-deficient (ob/ob) mice displayed higher levels of anxiety-related behaviour in both anxiety tests. In the appetitive Y-maze task, leptin deficiency caused no deficit in learning or re-learning and acute restrained stress had no influence on the learning process. CONCLUSIONS: These results emphasise that whilst leptin has previously been shown to modulate aversively motivated learning we found no difference between leptin-deficient mice and their controls in an appetitive learning task. Moreover, both groups showed behavioural flexibility under stressful conditions. On the other hand, leptin deficiency resulted in marked alterations in behaviours relevant to anxiety.


Subject(s)
Anxiety/genetics , Appetitive Behavior/physiology , Leptin/deficiency , Maze Learning/physiology , Obesity/psychology , Animals , Body Weight/genetics , Choice Behavior/physiology , Disease Models, Animal , Feeding Behavior/physiology , Leptin/genetics , Male , Mice , Mice, Obese , Obesity/genetics
17.
Eur J Pharmacol ; 639(1-3): 123-31, 2010 Aug 10.
Article in English | MEDLINE | ID: mdl-20371242

ABSTRACT

Understanding the complex interaction between stress and genetics that leads to the manifestation of disorders such as depression, anxiety, and cognitive dysfunction is one of the key areas of research in modern neuroscience. Growing evidence suggests that the glutamatergic system may be a relevant therapeutic target for such disorders. Glutamate is the neurotransmitter at the vast majority of excitatory synapses in the brain, and metabotropic glutamate (mGlu) receptor subtypes (mGlu(1) receptor-mGlu(8) receptor) act as important pre- and postsynaptic regulators of neurotransmission in the central nervous system (CNS), providing a mechanism by which fast synaptic responses through ligand-gated cation channels can be fine-tuned. Thus mGlu receptors are poised to participate in a wide variety of functions of the CNS. The presynaptic mGlu(7) receptor shows the highest evolutionary conservation within the family and it is thought to regulate neurotransmitter release. The mGlu(7) receptor is also the most widely distributed of the presynaptic mGlu receptors and is present at a broad range of synapses that are postulated to be critical for both normal CNS function and a range of psychiatric and neurological disorders. A growing body of evidence suggests that the mGlu(7) receptor is a key player in shaping synaptic responses at glutamatergic synapses as well as being a key regulator of inhibitory GABAergic transmission. The development of selective pharmacological and genetic tools has allowed for the unravelling of mGlu(7) receptor function in a host of physiological and behavioural processes. Knockout mice and siRNA knockdown has pointed to a role of the mGlu(7) receptor in anxiety, extinction of fear and aversion learning, spatial memory and the hormonal response to stress. In addition, these studies are largely supported by pharmacological manipulation of mGlu(7) receptor using the selective modulator N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), although paradoxical effects with this agonist have also emerged. Together these data suggest that the mGlu(7) receptor is an important regulator of glutamatergic function, of fear and aversion and cognition and thus this receptor represents an innovative therapeutic target for stress-related disorders at the interface of cognition and anxiety.


Subject(s)
Cognition/physiology , Emotions/physiology , Excitatory Amino Acid Agents/therapeutic use , Receptors, Metabotropic Glutamate/metabolism , Synaptic Transmission/drug effects , Animals , Cognition/drug effects , Emotions/drug effects , Excitatory Amino Acid Agents/pharmacology , Humans , Mental Disorders/drug therapy , Receptors, Metabotropic Glutamate/agonists , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Synaptic Transmission/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...